

Pacira BioSciences, Inc. 2024 Methodological Note

1. Purpose

The Association of British Pharmaceutical Industry (ABPI) Code of Practice requires member companies to publish a methodological note to accompany the annual disclosure of transfers of value made to health professionals, other relevant decision makers, and healthcare organisations located in Europe.

2. Scope

Pacira BioSciences, Inc., and its subsidiaries (collectively, "Pacira"), is a non-member of the ABPI that has agreed to comply with the ABPI Code and accept jurisdiction of The Prescription Medicines Code of Practice Authority ("PMCPA").

This methodological note applies to the disclosure of transfers of value ("ToV") made by Pacira in 2024, directly or indirectly, to health professionals ("HCPs"), other relevant decision makers ("ORDMs") and healthcare organisations ("HCOs") located in the United Kingdom ("UK").

This methodological note is intended to accompany Pacira's Disclosure UK report that includes reportable ToV made to HCOs located in the UK and members of the UK health professions in 2024.

3. Definitions

Health Professional (HCP): includes any member of the medical, dental, pharmacy or nursing profession and any other person who, in the course of their professional activities, may administer, prescribe, purchase, recommend or supply a medicine. In relation to the annual disclosure of transfers of value, the term also includes any employee of a pharmaceutical company whose primary occupation is that of a practicing health professional.

Other Relevant Decision Maker (ORDM): Includes someone with a National Health Service (NHS) role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply, or use of any medicine but who is not an HCP.

Healthcare Organisation (HCO): a healthcare, medical or scientific association or organisation such as a hospital, clinic, foundation, university or other teaching institution or learned society whose business address, place of incorporation or primary place of operation is in the UK or an organisation through which one or more health professionals or other relevant decision makers provide services.

If an HCO consists of only one health professional or other relevant decision maker, then it would be subject to the requirements in the Code regarding individual HCPs.

Transfer of Value ("ToV"): A direct or indirect transfer of value, whether in cash, in-kind or otherwise, made, whether for promotional purposes or otherwise, in connection with the development or sale of medicines. A direct transfer of value is one made directly by a company for the benefit of a recipient. An indirect transfer of value is one made on behalf of a company for the benefit of a recipient or through an intermediate and where the company knows or can identify the recipient that will benefit from the transfer of value.

Event: Includes scientific professional meetings, congresses, conferences, and other similar activities. Examples include rental of a stand space at a congress.

4. Reportable ToV

Sponsorship agreements with HCOs / third party organisations appointed by HCOs to manage an Event: Events include all scientific meetings, congresses, and conferences. Pacira sponsorship payments were made according to the agreed upon fees, terms, and conditions in duly executed sponsorship agreements with each HCO or third-party organisations appointed by the HCO.

Travel and Accommodation: This category includes the ToV for travel and accommodation attributable in relation to consultancy services of an HCP.

Fee for Service and Consultancy: This category includes the fees and any related expenses covered by a consultancy agreement with an HCP.

5. Payment Details

Currency: All reportable ToV are made and reported in GBP.

Value Added Tax (VAT): If VAT has been invoiced and paid to the HCO, VAT will be included in the ToV amount reported. Where payment of taxes is due, they are the responsibility of the recipient of the ToV and not Pacira.

ToV Date: The ToV date represents the actual date of payment.

6. Contacts

For inquiries related to this methodological note or Disclosure UK data, please contact compliance@pacira.com.